Background Patients with EGFR-mutant lung cancers treated with EGFR tyrosine kinase inhibitors (TKIs) develop clinical resistance, most commonly with acquisition of EGFR T790M. Evolutionary modeling suggests that a schedule of twice weekly pulse and daily low-dose erlotinib may delay emergence of EGFR T790M. Pulse dose erlotinib has superior central nervous system (CNS) penetration and may resu...

IMPORTANCE Tumor resistance is an emerging problem for Smoothened (SMO) inhibitor-treated metastatic basal cell carcinoma (BCC). Arsenic trioxide and itraconazole antagonize the hedgehog (HH) pathway at sites distinct from those treated by SMO inhibitors. OBJECTIVE To determine whether administration of intravenous arsenic trioxide and oral itraconazole in patients with metastatic BCC is asso...

Introduction: Scrub typhus is a febrile illness caused by Orientia tsutsugamushi which is transmitted by the larval stage of trombiculid mites. It has varied manifestations ranging from mild disease to fatal illness. The classical manifestations include fever, rash, lymphadenopathy and eschar. Serology is the preferred diagnostic tool with indirect immunofluorescence assay (IFA) as the current ...

A newborn male infant, with an estimated gestational age of 35weeks, was born via spontaneous vaginal delivery to a 28year-old mother, who presented in active labour with a macular rash on her hands and feet noted at the time of delivery, as shown in Fig. 1(c–e). Maternal history was significant for illicit drug use and scant prenatal care, without thorough serological evaluation performed prio...

Purpose: MORAb-009 is a chimeric monoclonal antibody that targets mesothelin, a tumor differentiation antigen overexpressed in pancreatic cancer, ovarian cancer, mesothelioma, and other malignancies. We conducted a phase I clinical trial of MORAb-009 in patients with advanced mesothelin-expressing cancers to determine its safety, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD). M...

PURPOSE MORAb-009 is a chimeric monoclonal antibody that targets mesothelin, a tumor differentiation antigen overexpressed in pancreatic cancer, ovarian cancer, mesothelioma, and other malignancies. We conducted a phase I clinical trial of MORAb-009 in patients with advanced mesothelin-expressing cancers to determine its safety, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD). ...

Abstract Background Human brucellosis is an infectious multisystem disease that varies in severity and clinical course. Bacteremia common; however, data on epidemiology management of Brucella bacteremia are scarce. The World Health Organization recommends using doxycycline with rifampicin or aminoglycoside for brucellosis. This study aims to compare the efficacy two treatment regimens (oral dox...

The current management of advanced hepatocellular carcinoma (HCC) is limited to systemic therapy alone. However the combination trans-arterial radioembolization (TARE) and therapies has been investigated in a small number retrospective studies. Results have shown that this generally safe. This study aimed safety efficacy combining TARE therapy. review was done for all patients with HCC (BCLC-C ...

e16131 Background: There are no approved peri-operative anti?cancer therapies for patients with hepatocellular cancer (HCC) who candidates liver resection (LR). Combination immunotherapy induces radiologically measurable responses in > 25% of HCC, providing a rationale neoadjuvant use surgical candidates. Methods: PRIME?HCC is two-part, multi-centre, phase Ib study to assess safety and bioac...